Researchers at Imperial College London have developed a technique to replicate biological structures using cryogenics and 3D printing. The research is a first from the university to create structures that are soft enough to replicate the mechanical properties of organs like the brain and lungs. The 3D printing technique could create replica organs and assist […]
Carmat gains on French approval to resume artificial heart trial
Carmat (EPA:ALCAR) shares are up today after the company said French regulators approved the resumption of a clinical trial for its artificial heart. France’s national device & drug agency, the Agence Nationale de Sécurité du Médicament, said late yesterday that “Carmat has provided the elements allowing for the resumption of the trial, meeting satisfactory conditions of safety and […]
Tissue-engineered human liver made from stem & progenitor cells
Researchers at the Saban Research Institute of Children’s Hospital in Los Angeles generated mouse and human tissue-engineered livers from organoid units composed of stem and progenitor cells, according to a study published in Stem Cells Translational Medicine last month. The tissue-engineered liver demonstrated normal attributes such as hepatocytes and blood cells and even restored some […]
SynCardia pulls $28m IPO
SynCardia Systems yesterday withdrew its plans for an initial public offering that was slated to fetch $27.5 million at the midpoint. “The registrant submits this request for withdrawal as it does not intend to pursue the contemplated public offering at this time,” the Tucson-based artificial heart maker said in an SEC filing. Syncardia had planned to float […]
Carmat to give 4th patient artificial heart within 3 months
(Reuters) — Carmat (FRA:CXT) will equip a 4th patient with an artificial heart within 3 months at most, 1 of the company’s founders told BFM television today. The French company is conducting trials of its heart device, which is designed as a permanent implant to extend the life of patients without them having to wait for a […]
Carmat: No problem with artificial heart fundamentals despite death
Euronext suspends Carmat shares after artificial heart patient dies
Carmat artificial heart patient ‘never felt so good’
Carmat shares surge on artificial heart patient’s hospital discharge
Vital Therapies prices $54M IPO
Vital Therapies priced its initial public offering at $12 per share, once again lowering the bar for its 1st public flotation after scuttling its 1st try at a U.S. IPO.
Vital Therapies, which is developing a bio-artificial liver, last October set the IPO’s price range at $16-$18. But the San Diego-based company but shelved the offering until March, when it set the range at $13-$15 per share.
Vital Therapies lowers the bar with 2nd IPO try
Bio-artificial liver maker Vital Therapies set the range for its initial public offering at $13 to $15 per share, below the $16 to $18 range it set last year before scuttling its 1st try at a U.S. IPO.
In March Vital Therapies filed updated registration statements signaling its intent to launch the IPO, wiping clean the pricing set in November 2013. Another filing today set the new price range for the 4.5-million-share offering at $58.5 million to $67.5 million.
